Educational information, not medical advice — ask your doctor or midwife.
Track Cytisine / Cytisinicline with reminders and record whether it helped, in the app.
Cytisine is a naturally occurring alkaloid found primarily in the seeds of Laburnum anagyroides (golden rain tree) and related legume species. It has been used as a smoking cessation aid in Eastern Europe — particularly Poland, Bulgaria, and Russia — since the 1960s under the brand name Tabex. Cytisinicline is a refined, pharmaceutical-grade form of the same molecule now being developed in the West by Achieve Life Sciences.
Cytisine binds to the same nicotine receptors (alpha-4 beta-2 nicotinic acetylcholine receptors) in the brain that nicotine targets, but it activates them only partially. This partial activation is enough to reduce withdrawal symptoms and cravings, while at the same time making smoking less rewarding because the receptors are already occupied. It works similarly to varenicline (Chantix) but comes from a plant source and has a decades-long safety record.
The traditional form (Tabex) is a 1.5 mg film-coated tablet taken on a tapering schedule over 25–30 days. Cytisinicline, the optimized clinical formulation, has been studied in 3 mg and 6 mg doses in phase 2 and 3 trials. Extended-release formulations are under investigation to improve tolerability.
Cytisine was isolated from Laburnum seeds in the 19th century and recognized as nicotinic by Soviet-era pharmacologists. Tabex was approved in Bulgaria in 1964 and has been widely used across Eastern Europe for 60+ years — giving cytisine one of the longest real-world safety records of any smoking cessation treatment.
Evidence grades and traditional-use labels are explained in our methodology. Nothing here is medical advice.
Reviewed by the HealisticMD editorial team How we grade evidence →
What it is typically used for, usual dose, cautions, and the study behind it where real trial data exists.
One email with the summary. We'll also send a short weekly evidence update — unsubscribe any time.